-+ 0.00%
-+ 0.00%
-+ 0.00%

Amneal Pharmaceuticals (AMRX) Lifted 2026 Guidance, Is It Still 12% Undervalued?

Simply Wall St·11/16/2026 05:26:42
Listen to the news

Amneal Pharmaceuticals (AMRX) has drawn fresh attention after raising its 2026 net revenue outlook, reporting higher third quarter and year-to-date sales, a quarterly net loss, and lower asset impairment charges.

At a share price of $21.38, Amneal Pharmaceuticals has seen momentum build, with an 11.47% 1 month share price return, a 17.54% 3 month share price return and a 68.88% year to date share price return. This has contributed to a very large 3 year total shareholder return of about 4x as investors respond to upgraded guidance, higher sales and lower impairment charges.

Compare Amneal Pharmaceuticals' momentum and guidance upgrade against hand picked peers by scanning the 35 high quality undervalued stocks that also pair solid fundamentals with potential mispricing.

For Amneal Pharmaceuticals, the sharp share price move now sits between two narratives. Are investors simply repricing better guidance and earnings progress, or has sentiment sprinted ahead of what the business fundamentals support?

Most Popular Narrative: 12% Undervalued

Amneal Pharmaceuticals' analyst consensus Narrative on Simply Wall St places fair value at about $24.29, compared with the latest close at $21.38. This frames the recent share price surge against a still supportive valuation backdrop based on those assumptions.

Amneal Pharmaceuticals is pursuing a deliberate shift toward complex generics such as transdermal patches, injectables, ophthalmics and drug device combinations. Management is targeting an additional US$1b to US$2b of Affordable Medicines revenue by 2030, which directly targets higher value revenue growth.

See why 21 investors see Amneal Pharmaceuticals as 12% undervalued.

Result: Fair Value of $24.29 (UNDERVALUED)

Still, pressure on U.S. generics pricing and higher capital spending that does not translate into stronger earnings could quickly challenge the current optimism surrounding Amneal Pharmaceuticals.

Find out about the key risks to this Amneal Pharmaceuticals narrative.

Another View On Amneal Pharmaceuticals Valuation

On price multiples, Amneal Pharmaceuticals looks far less generous than the 12% undervalued story suggests. The stock trades on a P/E of 55.9x, compared with 17.1x for the US Pharmaceuticals industry, 47.2x for peers, and a fair ratio of 33.8x. That gap points to real valuation risk if expectations cool.

To see how this premium stacks up against the underlying numbers and assumptions, See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:AMRX P/E Ratio as at Nov 2026
NasdaqGS:AMRX P/E Ratio as at Nov 2026

Next Steps

Mixed signals can feel messy, yet they are exactly when careful readers get an edge by weighing both caution and optimism on Amneal Pharmaceuticals. For a clearer picture of what the crowd is worried about and what it is excited by, review the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Amneal Pharmaceuticals?

If you stop with Amneal Pharmaceuticals, you only see one side of the market. Use the screener tools to spot opportunities others are leaving on the table.